PET在肿瘤方面应用的成本效益分析

顾爱春; 黄钢; 顾爱春; 黄钢

[1]

Valk PE,Pounds TR,Tesar RD,et al.Cost-effectiveness of PET imaging in clinical oncology.Nucl Med Biol,1996,23(6):737-743.

[2]

Gambhir SS,Shepherd JE,Shah BD,et al.Analytical decision model for the cost-effective management of solitary pulmonary nodules.J Clin Oncol,1998,16(6):2113-2125.

[3]

Miles KA.An approach to demonstrating cost-effectiveness of diagnostic imaging modalities in Australia illustrated by PET.Austr Radiol,2001,45(1):9-18.

[4]

Keith CJ,Miles KA,Griffiths MR,et al.Solitary pulmonary nodules:accuracy and cost-effectiveness of sodium iodide FDG-PET using Australian data.Eur J Nucl Med Mol Imaging,2002,29(8):1016-1023.

[5]

Kosuda S,Ichihara K,Watanabe M,et al.Decision-tree sensitivity analysis for cost-effectiveness of FDG-PET in patients with pulmonary nodules(non-small cell lung carcinoma) in Japan.Chest,2000,117(2):346-353.

[6]

Dietlein M,Weber K,Gandiour A,et al.Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules:a decision analysis based on cost reimbursement in Germany.Eur J Nucl Med,2000,27(10):1441-1456.

[7]

Gugiatti A,Grimaldi A,Rossetti C,et al.Economic analyses on the use of positron emission tomography for the work-up of solitary pulmonary nodules and for staging patients with non-small-celllung-cancer in Italy.Q J Nucl Med,2004,48(1):49-61.

[8]

Gambhir SS,Hoh CK,Phelps ME,et al.Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.J Nucl Med,1996,37(9):1428-1436.

[9]

Scott WJ,Shelpherd J,Gambhir SS.Cost-effectiveness of FDG-PET for staging non-small-cell lung carcinoma:a decision analysis.Ann Thorac Surg,1998,66(6):1876-1883.

[10]

Yap KK,Yap KS,Byrne AJ,et al.Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer.Eur J Nucl Med Mol Imaging,2005,32(9):1033-1040.

[11]

Alzahouri K,Lejeune C,Woronoff-Lemsi MC,et al.Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective.Clin Radiol,2005,60(4):479-492.

[12]

Sloka JS,Hollett PD,Mathews M.Cost-effectiveness of positron emission tomography for non-small cell lung carcinoma in Canada.Med Sci Monit,2004,10(5):MT73-MT80.

[13]

Nguyen VH,Peloquin S,Lacasse Y.Cost-effectiveness of positron emission tomography for the management of potentially operable non-small cell lung cancer in Quebec.Can Respir J,2005,12(1):19-25.

[14]

Kosuda S,Ichihara K,Watanabe M,et al.Decision-tree sensitivity analysis for cost-effectiveness of whole-body FDG PET in the management of patients with non-small cell lung carcinoma in Japan.Ann Nucl Med,2002,16(4):263-271.

[15]

Dietlein M,Weber K,Gandiour A,et al.Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer:priority for a PET-based strategy after nodal-negative CT results.Eur J Nucl Med,2000,27(11):1598-1609.

[16]

Zubeldia JM,Bednarczyk EM,Baker JG,et al.The economic impact of 18FDG positron emission tomography in the surgical management of colorectal cancer with hepatic metastases.Cancer Biother Radiopharm,2005,20(4):450-456.

[17]

Sloka JS,Hollett PD.Cost effectiveness of positron emission tomography in Canada.Med Sci Monit,2005,11(10):PH1-PH6.

[18]

Hollenbeak CS,Lowe VJ,Stack BC Jr.The cost-effectiveness of fluorodeoxyglucose 18-F positron emission tomography in the NO neck.Cancer,2001,92(9):2341-2348.

[19]

Bongers V,Hobbelink MG,van Rijk PP,et al.Cost-effectiveness ofdual-head ¹⁸F-fluorodeoxyglucose PET for the detection of recurrent laryngeal cancer.Cancer Biother Radiopharm,2002,17(3):303-306.

[20]

Hoh CK,Glaspy J,Rosen P,et al.Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma.J Nucl Med,1997,38(3):343-348.

[21]

Klose T,Leidl R,Buchmann I,et al.Primary staging of lymphomas:cost-effectiveness of FDG-PET versus computed tomography.Eur J Nucl Med,2000,27(10):1457-1464.

[22]

Sloka JS,Hollett PD,Mathews M.Cost-effectiveness of positron emission tomography in breast cancer.Mol Imaging Biol,2005,7(5):351-360.

[23]

Tsushima Y,Endo K.Analysis models to assess cost effectiveness of the four strategies for the work-up of solitary pulmonary nodules.Med Sci Monit,2004,10(5):MT65-MT72.